成人Still病诊疗进展

doi:10.35541/cjd.20190772

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 165-169.doi: 10.35541/cjd.20190772

成人Still病诊疗进展

易晓晴罗帅寒天张桂英陆前进

中南大学湘雅二医院皮肤科，长沙 410011

收稿日期:2019-07-26 修回日期:2020-02-10 发布日期:2021-01-29
通讯作者: 罗帅寒天 E-mail:lsht5309@csu.edu.cn
基金资助:
国家自然科学基金（81703133）；中南大学中央高校基本科研业务费专项资金（502211904）

Diagnosis and treatment of adult-onset Still′s disease

^{Yi Xiaoqing, Luo Shuaihantian, Zhang Guiying, Lu Qianjin}

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Received:2019-07-26 Revised:2020-02-10 Published:2021-01-29
Contact: Luo Shuaihantian E-mail:lsht5309@csu.edu.cn
Supported by:
National Natural Science Foundation of China （81703133）; Fundamental Research Funds for the Central Universities of Central South University （502211904）

摘要/Abstract

摘要： 【摘要】成人Still病是一类病因未明的全身炎症性疾病，临床表现多样，其诊断和治疗存在一定困难。近年来发现，血红素加氧酶1、钙网蛋白、炎症细胞因子、糖基化终末产物等新型标志物可对成人Still病的活动程度和严重程度进行全面评估，而新研发的生物制剂如肿瘤坏死因子抑制剂、白细胞介素1（IL-1）抑制剂、IL-6抑制剂、重组IL-18结合蛋白也有望用于治疗。本文主要综述成人Still病的诊断和治疗进展。

关键词: 诊断, 生物学标记, 治疗, 生物制剂, 成人Still病

Abstract: 【Abstract】 Adult-onset Still′s disease （AOSD） is a type of systemic inflammatory disease of unknown etiology, with diverse clinical manifestations, and there are some difficulties in its diagnosis and treatment. In recent years, it has been found that some new markers, such as heme oxygenase 1, calreticulin, inflammatory cytokines and advanced glycation end products, can be used for a comprehensive assessment of the activity and severity of AOSD. Moreover, new biological agents, such as tumor necrosis factor inhibitors, interleukin-1 (IL-1) inhibitors, IL-6 inhibitors and recombinant IL-18 binding proteins, bring new hope for the treatment of AOSD. This review mainly summarizes progress in the diagnosis and treatment of AOSD.

Key words: Diagnosis, Biological markers, Therapy, Biological agents, Adult-onset Still′s disease

易晓晴罗帅寒天张桂英陆前进. 成人Still病诊疗进展[J]. 中华皮肤科杂志, 2021,54(2):165-169. doi:10.35541/cjd.20190772

Yi Xiaoqing, Luo Shuaihantian, Zhang Guiying, Lu Qianjin. Diagnosis and treatment of adult-onset Still′s disease[J]. Chinese Journal of Dermatology, 2021, 54(2): 165-169.doi:10.35541/cjd.20190772

参考文献 55

［1］	Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still′s disease［J］. J Rheumatol, 1996,23（3）:495⁃497.
［2］	Cush JJ, Medsger TA Jr, Christy WC, et al. Adult⁃onset Still′s disease. Clinical course and outcome［J］. Arthritis Rheum, 1987,30（2）:186⁃194. doi: 10.1002/art.1780300209.
［3］	Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still′s disease［J］. J Autoimmun, 2018,93:24⁃36. doi: 10.1016/j.jaut.2018.07.018.
［4］	Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still′s disease［J］. J Rheumatol, 1992,19（3）:424⁃430.
［5］	Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult⁃onset still disease［J］. Medicine （Baltimore）, 2002,81（3）:194⁃200. doi: 10.1097/00005792⁃200205000⁃00003.
［6］	Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance［J］. Am J Med, 1995,98（6）:566⁃571. doi: 10.1016/s0002⁃9343（99）80015⁃1.
［7］	Fautrel B, Le Moël G, Saint⁃Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still′s disease［J］. J Rheumatol, 2001,28（2）:322⁃329.
［8］	Vignes S, Le Moël G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still′s disease［J］. Ann Rheum Dis, 2000,59（5）:347⁃350. doi: 10.1136/ard.59.5.347.
［9］	Kirino Y, Kawaguchi Y, Tada Y, et al. Beneficial use of serum ferritin and heme oxygenase⁃1 as biomarkers in adult⁃onset Still′s disease: a multicenter retrospective study［J］. Mod Rheumatol, 2018,28（5）:858⁃864. doi: 10.1080/14397595.2017.1422231.
［10］	Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease［J］. Arthritis Rheum, 2004,50（12）:3762⁃3771. doi: 10.1002/art.20631.
［11］	Kim HA, Han JH, Kim WJ, et al. TLR4 endogenous ligand S100A8/A9 levels in adult⁃onset Still′s disease and their association with disease activity and clinical manifestations［J］. Int J Mol Sci, 2016,17（8）. doi: 10.3390/ijms17081342.
［12］	Jung SY, Park YB, Ha YJ, et al. Serum calprotectin as a marker for disease activity and severity in adult⁃onset Still′s disease［J］. J Rheumatol, 2010,37（5）:1029⁃1034. doi: 10.3899/jrheum.091120.
［13］	Mitrovic S, Fautrel B. New markers for adult⁃onset Still′s disease［J］. Joint Bone Spine, 2018,85（3）:285⁃293. doi: 10.1016/j.jbspin.2017.05.011.
［14］	Kudela H, Drynda S, Lux A, et al. Comparative study of Interleukin⁃18 （IL⁃18） serum levels in adult onset Still′s disease （AOSD） and systemic onset juvenile idiopathic arthritis （sJIA） and its use as a biomarker for diagnosis and evaluation of disease activity［J］. BMC Rheumatol, 2019,3:4. doi: 10.1186/s41927⁃019⁃0053⁃z.
［15］	Priori R, Colafrancesco S, Alessandri C, et al. Interleukin 18: a biomarker for differential diagnosis between adult⁃onset Still′s disease and sepsis［J］. J Rheumatol, 2014,41（6）:1118⁃1123. doi: 10.3899/jrheum.130575.
［16］	Shimizu M, Kizawa T, Kato R, et al. Macrophage activation syndrome in neonates born to mothers with adult⁃onset Still′s disease: perinatal effect of maternal IL⁃18［J］. Clin Immunol, 2019,207:36⁃39. doi: 10.1016/j.clim.2019.07.005.
［17］	Sun Y, Wang Z, Chi H, et al. Elevated serum levels of interleukin⁃10 in adult⁃onset Still′s disease are associated with disease activity［J］. Clin Rheumatol, 2019,38（11）:3205⁃3210. doi: 10.1007/s10067⁃019⁃04642⁃x.
［18］	Chi H, Liu D, Sun Y, et al. Interleukin⁃37 is increased in adult⁃onset Still′s disease and associated with disease activity［J］. Arthritis Res Ther, 2018,20（1）:54. doi: 10.1186/s13075⁃018⁃1555⁃6.
［19］	Shimojima Y, Kishida D, Ueno KI, et al. Characteristics of circulating natural killer cells and their interferon⁃γ production in active adult⁃onset Still disease［J］. J Rheumatol, 2019,46（10）:1268⁃1276. doi: 10.3899/jrheum.181192.
［20］	Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult⁃onset Still′s disease: the implications of current and emerging markers in overcoming the diagnostic challenge［J］. Expert Rev Clin Immunol, 2015,11（6）:749⁃761. doi: 10.1586/1744666X.2015.1037287.
［21］	Han JH, Ahn MH, Jung JY, et al. The levels of CXCL12 and its receptor, CXCR4, as a biomarker of disease activity and cutaneous manifestation in adult⁃onset Still′s disease［J］. Clin Exp Rheumatol, 2019,37 Suppl 121（6）:67⁃73.
［22］	Kim HA, Kim YH, Jeon YK, et al. Histopathology and expression of the chemokines CXCL10, CXCL13, and CXCR3 and the endogenous TLR⁃4 ligand S100A8/A9 in lymph nodes of patients with adult⁃onset Still′s disease［J］. Sci Rep, 2019,9（1）:7517. doi: 10.1038/s41598⁃019⁃44032⁃6.
［23］	Chen DY, Chen YM, Lin CC, et al. The potential role of advanced glycation end products （AGEs） and soluble receptors for AGEs （sRAGE） in the pathogenesis of adult⁃onset still′s disease［J］. BMC Musculoskelet Disord, 2015,16:111. doi: 10.1186/s12891⁃015⁃0569⁃3.
［24］	Hu Q, Gong W, Gu J, et al. Plasma microRNA profiles as a potential biomarker in differentiating adult⁃onset Still′s disease from sepsis［J］. Front Immunol, 2018,9:3099. doi: 10.3389/fimmu.2018.03099.
［25］	Siddiqui M, Putman MS, Dua AB. Adult⁃onset Still′s disease: current challenges and future prospects［J］. Open Access Rheumatol, 2016,8:17⁃22. doi: 10.2147/OARRR.S83948.
［26］	Colina M, Zucchini W, Ciancio G, et al. The evolution of adult⁃onset Still disease: an observational and comparative study in a cohort of 76 Italian patients［J］. Semin Arthritis Rheum, 2011,41（2）:279⁃285. doi: 10.1016/j.semarthrit.2010.12.006.
［27］	Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult⁃onset Still′s disease: a study of 104 cases［J］. Clin Rheumatol, 2010,29（9）:1015⁃1019. doi: 10.1007/s10067⁃010⁃1516⁃1.
［28］	Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still′s disease （AOSD） in the era of biologic therapies: dichotomous view for cytokine and clinical expressions［J］. Autoimmun Rev, 2014,13（11）:1149⁃1159. doi: 10.1016/j.autrev.2014.08.032.
［29］	Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still′s disease: a systematic review and meta⁃analysis of observational studies［J］. Expert Rev Clin Immunol, 2017,13（11）:1089⁃1097. doi: 10.1080/1744666X.2017.1375853.
［30］	Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult⁃onset Still′s disease［J］. Clin Rev Allergy Immunol, 2020,58（1）:71⁃81. doi: 10.1007/s12016⁃019⁃08747⁃8.
［31］	Vitale A, Cavalli G, Colafrancesco S, et al. Long⁃term retention rate of anakinra in adult onset Still′s disease and predictive factors for treatment response［J］. Front Pharmacol, 2019,10:296. doi: 10.3389/fphar.2019.00296.
［32］	Vercruysse F, Barnetche T, Lazaro E, et al. Adult⁃onset Still′s disease biological treatment strategy may depend on the phenotypic dichotomy［J］. Arthritis Res Ther, 2019,21（1）:53. doi: 10.1186/s13075⁃019⁃1838⁃6.
［33］	Lyseng⁃Williamson KA. Anakinra in Still′s disease: a profile of its use［J］. Drugs Ther Perspect, 2018,34（12）:543⁃553. doi: 10.1007/s40267⁃018⁃0572⁃5.
［34］	Castañeda S, Atienza⁃Mateo B, Martín⁃Varillas JL, et al. Anakinra for the treatment of adult⁃onset Still′s disease［J］. Expert Rev Clin Immunol, 2018,14（12）:979⁃992. doi: 10.1080/1744666X.2018.1536548.
［35］	Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult⁃onset Still disease: a meta⁃analysis of its efficacy and safety［J］. Drug Des Devel Ther, 2014,8:2345⁃2357. doi: 10.2147/DDDT.S73428.
［36］	Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin⁃1 inhibitors in 140 Italian patients with adult⁃onset Still′s disease: a multicentre retrospective observational study［J］. Front Pharmacol, 2017,8:369. doi: 10.3389/fphar.2017.00369.
［37］	Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL⁃1β long⁃acting inhibitor, in refractory adult⁃onset Still′s disease［J］. Semin Arthritis Rheum, 2012,42（2）:201⁃205. doi: 10.1016/j.semarthrit.2012.03.004.
［38］	Barsotti S, Neri R, Iacopetti V, et al. Successful treatment of refractory adult⁃onset still disease with canakinumab: a case report［J］. J Clin Rheumatol, 2014,20（2）:121. doi: 10.1097/RHU.0000000000000082.
［39］	Castañeda S, Martínez⁃Quintanilla D, Martín⁃Varillas JL, et al. Tocilizumab for the treatment of adult⁃onset Still′s disease［J］. Expert Opin Biol Ther, 2019,19（4）:273⁃286. doi: 10.1080/14712598.2019.1590334.
［40］	Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult⁃onset Still′s disease: a retrospective, single⁃center study［J］. Mod Rheumatol, 2015,25（3）:401⁃404. doi: 10.3109/14397595.2014.973659.
［41］	Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult⁃onset Still′s disease: results from a case series［J］. Clin Rheumatol, 2014,33（1）:49⁃55. doi: 10.1007/s10067⁃013⁃2381⁃5.
［42］	Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin⁃6 in adult⁃onset Still′s disease: a meta⁃analysis［J］. Mod Rheumatol, 2018,28（5）:849⁃857. doi: 10.1080/14397595.2017.1416924.
［43］	Gabay C, Fautrel B, Rech J, et al. Open⁃label, multicentre, dose⁃escalating phase II clinical trial on the safety and efficacy of tadekinig alfa （IL⁃18BP） in adult⁃onset Still′s disease［J］. Ann Rheum Dis, 2018,77（6）:840⁃847. doi: 10.1136/annrheumdis⁃2017⁃212608.
［44］	Yang XP, Wang M, Li TF, et al. Predictive factors and prognosis of macrophage activation syndrome associated with adult⁃onset Still′s disease［J］. Clin Exp Rheumatol, 2019,37 Suppl 121（6）:83⁃88.
［45］	Ruscitti P, Iacono D, Ciccia F, et al. Macrophage activation syndrome in patients affected by adult⁃onset Still disease: analysis of survival rates and predictive factors in the gruppo italiano di ricerca in reumatologia clinica e sperimentale cohort［J］. J Rheumatol, 2018,45（6）:864⁃872. doi: 10.3899/jrheum.170955.
［46］	Mitrovic S, Fautrel B. Complications of adult⁃onset Still′s disease and their management［J］. Expert Rev Clin Immunol, 2018,14（5）:351⁃365. doi: 10.1080/1744666X.2018.1465821.
［47］	Chamseddin B, Marks E, Dominguez A, et al. Refractory macrophage activation syndrome in the setting of adult⁃onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus［J］. J Cutan Pathol, 2019,46（7）:528⁃531. doi: 10.1111/cup.13466.
［48］	Junge G, Mason J, Feist E. Adult onset Still′s disease⁃the evidence that anti⁃interleukin⁃1 treatment is effective and well⁃tolerated （a comprehensive literature review）［J］. Semin Arthritis Rheum, 2017,47（2）:295⁃302. doi: 10.1016/j.semarthrit.2017.06.006.
［49］	Efthimiou P, Kadavath S, Mehta B. Life⁃threatening complications of adult⁃onset Still′s disease［J］. Clin Rheumatol, 2014,33（3）:305⁃314. doi: 10.1007/s10067⁃014⁃2487⁃4.
［50］	Gerfaud⁃Valentin M, Maucort⁃Boulch D, Hot A, et al. Adult⁃onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients［J］. Medicine （Baltimore）, 2014,93（2）:91⁃99. doi: 10.1097/MD.0000000000000021.
［51］	Narváez J, Mora⁃Limiñana M, Ros I, et al. Pulmonary arterial hypertension in adult⁃onset Still′s disease: a case series and systematic review of the literature［J］. Semin Arthritis Rheum, 2019,49（1）:162⁃170. doi: 10.1016/j.semarthrit.2018.11.007.
［52］	Néel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life⁃threatening adult⁃onset Still disease: a French nationwide multicenter study and systematic literature review［J］. Crit Care, 2018,22（1）:88. doi: 10.1186/s13054⁃018⁃2012⁃2.
［53］	Masson C, Le Loët X, Lioté F, et al. Adult Still′s disease. Part II. Management, outcome, and prognostic factors［J］. Rev Rhum Engl Ed, 1995,62（11）:758⁃765.
［54］	Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still′s disease: manifestations, disease course, and outcome in 62 patients［J］. Medicine （Baltimore）, 1991,70（2）:118⁃136.
［55］	Jamilloux Y, Gerfaud⁃Valentin M, Henry T, et al. Treatment of adult⁃onset Still′s disease: a review［J］. Ther Clin Risk Manag,2015,11:33⁃43. doi: 10.2147/TCRM.S64951.

[1]	张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767.
[2]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[3]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[4]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[5]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[6]	李锁向睿宇李志量荆可王媛张寒梅冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237.
[7]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[8]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[9]	张婷婷朱凤仪杨梅张平夏萍周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644.
[10]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694.
[11]	李赛, 薛华忠, 张树文, 蒋娟, 齐淑贞, 赵园园, 张津萍, 沙仲, 乐文静, 王碧伟, 赵诗轩, 朱小凤, 苏晓红. 多西环素-莫西沙星序贯疗法治疗生殖支原体尿道炎/宫颈炎的临床观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210631-e20210631.
[12]	黄雅馨, 何渊民, 黄书莉, 熊霞, 邓永琼. 血清几丁质酶3样蛋白1水平在寻常型天疱疮中的临床意义研究[J]. 中华皮肤科杂志, 2022, 0(2): 20210155-e20210155.
[13]	焦晓燕, 尹光文, 阴亚坤, 李冬芹. 妊娠期、围生期带状疱疹25例临床分析[J]. 中华皮肤科杂志, 2022, 0(2): 20210384-e20210384.
[14]	王佳绮, 王平, 李刘雨, 樊奇敏, 朱蒙燕, 王燕清, 周鸿宇, 沈宏, 许爱娥. 皮肤色素减退性淋巴增殖性疾病41例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(2): 110-115.
[15]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.

成人Still病诊疗进展

Diagnosis and treatment of adult-onset Still′s disease

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

Metrics

本文评价

推荐阅读 10